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ABSTRACT
Introduction Accurate blood glucose measurements are 
important in persons with diabetes during normal daily 
activities (NDA), even more so during exercise. We aimed 
to investigate the performance of fluorescence sensor- 
based and glucose oxidase- based interstitial glucose 
measurement during (intensive) exercise and NDA.
Research design and methods Prospective, observational 
study in 23 persons with type 1 diabetes when mountain 
biking for 6 days, followed by 6 days of NDA. Readings of 
the Eversense (fluorescence- based continuous glucose 
monitoring (CGM); subcutaneously implanted) and of the 
Free Style Libre (FSL; glucose oxidase- based flash glucose 
monitoring (FGM); transcutaneously placed) were compared 
with capillary glucose levels (Free Style Libre Precision 
NeoPro strip (FSLCstrip)).
Results Mean average differences (MAD) and mean 
average relative differences (MARD) were significantly 
different when comparing exercise with NDA (reference 
FSLCstrip); Eversense MAD 25±19 vs 17±6 mg/dL 
(p<0.001); MARD 17±6 vs 13%±6% (p<0.01) and FSL 
MAD 32±17 vs 18±8 mg/dL (p<0.01); MARD 20±7 vs 
12%±5% (p<0.001).
When analyzing the data according to the Integrated 
Continuous Glucose Monitoring Approvals (class II–510(K) 
guidelines), the overall performance of interstitial glucose 
readings within 20% of the FSLCstrip during exercise 
compared with NDA was 69% vs 81% for the Eversense 
and 59% vs 83% for the FSL, respectively. Within 15% of 
the FSLCstrip was 59% vs 70% for the Eversense and 46% 
vs 71% for the FSL.
Conclusions During exercise, both fluorescence and 
glucose oxidase- based interstitial glucose measurements 
(using Eversense and FSL sensors) were less accurate 
compared with measurements during NDA. Even when 
acknowledging the beneficial effects of CGM or FGM, users 
should be aware of the risk of diminished accuracy of 
interstitial glucose readings during (intensive) exercise.
INTRODUCTION
Regular exercise by persons with diabetes 
mellitus (DM) contributes to physiological 
and health benefits on the short and long 
term.1–3 Maintaining acceptable glucose 
concentrations during sports activities is chal-
lenging, however. The more intense the sport 
activity and the more extreme the conditions, 
the larger the challenge of balancing energy 
intake and insulin use. Therefore, particu-
larly during exercise, timely and accurate 
blood glucose readings are of importance to 
enhance chances on good metabolic control, 
allowing maximal performance.
During strenuous circumstances, an alter-
native to capillary self- measurement of 
blood glucose (SMBG) levels performed is 
Significance of this study
What is already known about this subject?
 ► Despite reasonable good accuracy of interstitial glu-
cose registrations under standardized conditions, 
interstitial glucose readings during exercise do tend 
to be less accurate.
 ► Qualitatively comparable glucose results of real- time 
continuous glucose monitoring and flash glucose 
monitoring show differences in accuracy.
What are the new findings?
 ► During exercise, interstitial glucose readings in-
deed are less accurate compared with readings 
during normal daily life activities, often with clini-
cally relevant differences, compared with capillary 
measurements.
How might these results change the focus of 
research or clinical practice?
 ► Persons with diabetes mellitus and healthcare pro-
viders should be aware of the pitfalls when interpret-
ing glucose interstitial readings during exercise, and 
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interstitial glucose measurements. At present, real- time 
continuous glucose monitoring (rt- CGM) and flash 
glucose monitoring (FGM) are available as methods for 
interstitial glucose measurements. If used appropriately, 
with rt- CGM the user often only needs to calibrate the 
sensor at some time points daily and being able to act 
and react on alarms preset at certain cut- off points. In 
contrast, FGM users use a factory- calibrated sensor, which 
with the presently available version in The Netherlands 
needs scanning for obtaining the required information.4
Some authors report qualitatively comparable glucose 
results of rt- CGM and FGM,5 although others observed 
differences in accuracy.6 However, these comparative 
studies are virtually always done under routine or stan-
dardized clinical circumstances. With such standardized 
testing, it can be assumed that factors such as interstitial 
fluid dynamics and interstitial glucose concentrations will 
behave more or less in a stable pattern during the testing 
periods. In contrast, real- life (intensive) exercise most 
likely will lead to more frequent and profound changes in 
interstitial fluid dynamics and thus in interstitial glucose 
concentration.7 Therefore, performance of interstitial 
glucose measurements might be quite different during 
intensive exercise conditions as compared with a perfor-
mance during normal daily activities (NDA). Further-
more, depending on the technique used to measure 
interstitial glucose concentrations, the change in inter-
stitial fluid dynamics might also affect reading outcomes 
differently.
In an earlier study, we found that during NDA and 
standardized tests FGM reading showed lower glucose 
concentrations than actually present with capillary 
measurements in the lower ranges, and higher than 
found in the higher ranges.8 In contrast, FGM perfor-
mance proved to be different during intensive exer-
cise in a real- life setting, showing comparatively higher 
glucose readings than actually present, but also less accu-
racy throughout the whole measurement spectrum.9 
The rt- CGM performance during exercise in that study 
also was less accurate than hoped for. Both the FGM and 
rt- CGM devices used in that study used a glucose oxidase 
based method for measuring glucose.10 11
Recently, an implantable rt- CGM device has been intro-
duced (Eversense), using fluorescence- based glucose 
measurement technique,12 with an accuracy comparable 
to other rt- CGM devices.13 The Eversense is an implant-
able rt- CGM device, needs calibrating twice daily, and 
ideally functions for 6 months. The Free Style Libre 
(FSL) FGM system has a transcutaneous probe, is factory 
calibrated and functions for 14 days.
Given the importance of reliable glucose measure-
ments during intensive exercise, we aimed to compare in 
a real- life setting the accuracy of two interstitial devices 
that use both a different method (glucose oxidase based 
vs fluorescence based) to measure glucose in persons 
with type 1 diabetes mellitus (T1DM). Furthermore, 
since differences in accuracy may differ depending on 
the circumstances and activity level,14 measurements 
were also performed during a period of NDA with no 
sports activities in the week after the mountain biking.
RESEARCH DESIGN AND METHODS
Study design
This was a prospective, observational study. The aim was 
to compare two different methods for interstitial glucose 
measurements: fluorescence based (using the Eversense) 
versus glucose oxidase based (using FSL) in two consec-
utive time periods, with first a 6- day period of intensive 
exercise, followed by a 6- day period of NDA.
Capillary glucose measurements were performed 
with Precision Neo Pro strips (Free Style Libre Capil-
lary glucose measurement strip (FSLCstrip)).8 In earlier 
research, this capillary measurement strip was verified to 
be closely comparable with National Institute of Standards 
and Technology (NIST) standards to the gold reference 
method (y=0.974 x−0.294, correlation 0.995).8 15 There-
fore, it was decided to use the results of the FSLCstrip as 
the reference values.
Setting and participants
This study was performed during the Bas van de Goor 
Foundation ‘webike2changediabetes’ challenge in 
September 2018 and in the week after the challenge 
(NDA, no sports activities). The Bas van de Goor Foun-
dation is a non- profit organization that aims to promote 
sports and exercise in persons with DM. During the 
current challenge, a combined team of 29 persons with 
27 T1DM and 2 type 2 diabetes mellitus from Spain and 
The Netherlands mountain biked in the Sierra Nevada, 
over a total distance of 263 km and a variable amount of 
altitude meters spread over the days (in total minimal 
4753 up to 11 000 m) https:// bvdgf. org/ evenementen/ 
evenement/ 27041/ webi ke2c hang edia betes- 2018/. The 
maximum altitude reached was 3398 m,16 but only for a 
short period of time. All participants in the Bas van de 
Goor Foundation challenge ‘webike2changediabetes’ in 
September 2018 were asked to participate in the study.
Procedures
Eventually, 23 participants with T1DM of total of the 27 
participants agreed to be included in the study. After 
obtaining written informed consent, baseline charac-
teristics were collected before and at start of the chal-
lenge. Eversense devices were implanted in the back of 
the upper arm, at one center in The Netherlands and 
several centers in Spain in the month of August 2018, 
according to the operating instructions, and by certified 
care professionals. FSL were inserted prior (>12 hours) 
to the challenge on the back of the opposite upper arm. 
The algorithm used to assess the readings of the Ever-
sense was the same as in the Precise I study,13 (being 
the initial Eversense algorithm; since then, a new algo-
rithm has been implemented) for the FSL the FSL’s first 
glucose known algorithm was used with the first available 
version of the FSL without the alarm functions as present 
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Participants were asked to perform a total of (at least) 7 
SMBGs per day using FSLCstrip test strips with the blood 
glucose meter incorporated in the FSL reader. Partic-
ipants scanned the glucose value with the FSL reader, 
performed a finger prick and finished with another 
scan with the FSL reader. The maximum time allowed 
between the two scans was 2 min. Participants were asked 
to perform extra SMBGs if necessary, for instance, when 
experiencing symptoms related to hypoglycemia. Ever-
sense and FSL readings, taken within maximal 2 min of 
the capillary FLSCstrip measurement, were considered 
to be valid for comparison. For the Eversense, two FSLC-
strip measurements per day were used for the calibration 
of the Eversense: these two calibration measurements 
were not included in the analysis comparing the read-
ings of the both interstitial measuring devices and the 
FSLCstrip.
Outcomes
Primary outcome of the present study was the accuracy of 
both methods for interstitial glucose measurements fluo-
rescence based (Eversense) versus glucose oxidase (FSL) 
with the FLSCstrip during exercise and during NDA. 
Results related to accuracy were (primarily) assessed by 
calculating mean absolute differences (MAD), mean 
absolute relative differences (MARD). Since control 
frequency was different between participants, MAD 
and MARD were calculated per person, not per glucose 
measurement (ie, for each participant, MAD and MARD 
was calculated for each measurement, and the individual 
MADs and MARDs were translated into a mean MAD and 
MARD for each participant, both for the exercise period 
and the NDA period.
Secondary outcomes included the accuracy of the 
interstitial readers when assessed according to the cut- 
off points as formulated in the Integrated Continuous 
Glucose Monitoring Approvals (class II–510(K) guide-
lines) (ICGMA guidelines)17 and comparisons between 
exercise and NDA with the Parkes error grid analysis. For 
the latter purpose, Eversense, FSL and FSLCstrip read-
ings in the two defined periods were fitted on the error 
grids as described by Parkes et al.18
Statistical methods
Data were expressed as number (percentage), mean 
(SD) or median (IQR) for normally distributed and non- 
normally distributed data, respectively. Normality was 
examined with Q- Q plots.
Concerning measurements maximally 2 min apart, the 
MAD and MARD between the Eversence and FSL were 
compared. For comparison of the exercise condition and 
NDA (subsequent weeks), data were analyzed as summary 
measure, that is, the average MAD and MARD for each 
participant during both conditions was used for analysis. 
Data were tested using the paired t- test.
The comparison with the cut- off points as formulated 
in the ICGMA guidelines17 was purely descriptive.
For risk assessment of possible differences between 
interstitial- based glucose values versus FSLCstrip measure-
ments, a Parkes error grid analysis, with percentage of 
measurements within consensus error grid zones, was 
performed. Values in zones A and B are deemed clini-
cally acceptable, whereas those in zones C, D and E are 
considered potentially unsafe.
Where applicable, a significance level of 5% was used. 
Analyses were performed using SPSS V.25.0 (IBM SPSS 
Statistics, Armonk, New York, USA) and Microsoft Excel 
Analyse- It (2010).
RESULTS
Baseline characteristics of the 23 study participants with 
T1DM are shown in table 1.
When looking at the combined glucose measurement 
results performed according to protocol, in total 908 data 
sets were considered suitable for analysis for Eversense 
and FSL with FSLCstrip comparison in the exercise week, 
and 814 combined data sets suitable for analysis of the 
NDA week. The difference in scan results in both weeks 
between the two FSL scan readings performed before 
and after the FSLCstrip measurement was 0–2 mg/dL 
with a few (<1%) readings up to 5 mg/dL, indicating 
that during the vast majority of readings the situation was 
sufficiently stable to allow comparison with the capillary 
readings. For calculation, the readings of the Eversense 
and FSL that are closest to the FSLC in terms of time 
were used.
Table 2 shows the differences in glucose readings in 
total, and in the ranges ≤70, 71–180 and >180 mg/dL.
In general, Eversense readings were significantly lower 
both during exercise and NDA (except for the hypogly-
cemic ranges where small numbers of pairs were present 
(n=61 and n=49)), whereas the FSL readings were signifi-
cantly higher during exercise, but not different from the 
FSLCstrip readings during NDA.
In table 3, results are shown of 22 of the 23 participants.
In one participant, the FSL sensor came loose from the 
arm (impacted) during the NDA week, which precluded 
inclusion of this one patient in the analysis. MADs and 
MARDs of Eversense and FSL compared with FSLCstrip 
were significantly higher during exercise compared with 
NDA; Eversense: MAD 25±10 vs 17±6 mg/dL (p<0.001) 
Table 1 Baseline characteristics
n=23
Age (years) 43 (18–56)
Female (%) 3 (13)
HbA1c (mmol/mol) 52 (36–76)
Diabetes duration (years) 17 (4–27)
MDI/CSII 14/9
Data are presented as n (%) or median (range).
CSII, Continuous Subcutaneous Insulin Infusion; HbA1c, 
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and MARD 17±6 vs 13%±6% (p=0.004); FSL: MAD 32±17 
vs 18±8 mg/dL (p=0.002) and MARD 20±7 vs 12%±5% 
(p<0.001).
When analyzing the data according to the ICGMA 
guidelines,18 performance during the exercise week does 
not reach the agreed on cut- off levels in either category 
of glucose levels or in total (table 4).
This failure to reach those levels is especially 
pronounced with the stricter cut- off levels. The situation 
improves when assessing performance during the NDA 
period.
When assessing the performance of the Eversense CGM 
during exercise compared with the FSLCstrip, 98.3% of 
the comparisons fell within zones A and B (73.2% and 
25.1%, respectively) of Parkes error grid analysis, with 
the slope following closely the x=y line: y=1.010 x−9.88, 
correlation 0.883 (figure 1A). In the NDA week, the Ever-
sense versus FSLCstrip comparison showed 98.8% of the 
comparison within zones A and B (81.9% and 16.9%, 
respectively), again with the slope closely following the 
x=y line: y=0.96 x−0.11, correlation 0.920; figure 1B). 
Assessing the comparative readings during daily activi-
ties in zone B, the Eversense CGM tends to show slightly 
lower concentrations than measured by capillary assess-
ment, this in contrast to the observations with the FSL.
During exercise, only few comparative readings of 
FSL compared with FSLCstrip were outside the zones 
A and B, 98.2% (73.9% and 24.3%, respectively), with a 
majority (84%) of the B readings in the upper B region 
(figure 2A). The slope of the comparison line was 1.21, 
which allowed the conclusion, especially with higher 
glucose concentrations, that the flash FSL tends to show 
higher readings compared with capillary measurements 
(y=1.21 x−10.13, correlation 0.917). FSL measurements 
during NDA were well correlated to the FSLC measure-
ments, with 99.9% of the points within the zones A and 
B (87.1% and 12.8%, respectively); the slope was 1.07 
(y=1.07 x−9.57), with a correlation of 0.937; figure 2B).
DISCUSSION
In this study we demonstrated that when testing two 
different interstitial glucose measurement techniques, 
both the Eversense (fluorescence based) and FSL (glucose 
oxidase based) are less accurate during a period of exer-
cise compared with a period of NDA. Importantly, differ-
ences are notable and relevant in virtually all categories. 
MAD and MARD during an exercise period are higher 
than during NDA, allowing the conclusion that both 
devices show less accuracy during exercise than during 
NDA. This conclusion is confirmed when measurements 
are assessed according to the ICGMA guidelines.
It has been shown that a reasonable or even high 
correlation between interstitial readings and capillary 
blood glucose concentrations is no guarantee for accu-
racy, and other measures such as MAD and MARD are 
needed for interpretation of the true accuracy.5 Even 
reporting overall MAD and MARD is an insufficient guar-
antee for adequate or even acceptable accuracy in the 
region that matters most to people with DM: the hypo-
glycemic range. Therefore, we advocate not restricting 
descriptions with regard to accuracy to a correlation (or 
correlations square) or overall MARD alone, and for 
comparison to adhere to the proposed ICGMA guide-
lines. Furthermore, even with rather high correlations as 
this study for example, for FSL during exercise (r=0.917; 
r²=0.841) and during daily activities (r=0.937; r²=0.878), 
there are considerable differences in MAD, MARD and 
performance according to the ICGMA guidelines. This 
again allows the conclusion that results of performance 
measurements need to be interpreted in context. Of 
course, first assessments need to be done under stan-
dardized conditions, but when interstitial measurement 
techniques are introduced and used in daily practice, 
probably (many) more factors need to be taken into 
account compared with venous and capillary blood 
measurements.
Table 2 Comparisons at various glucose concentrations of 











≤70 61 58±10 59±15 73±17**
71–180 544 125±30 117±39** 142±43**
>180 303 241±53 222±59** 276±76**
Total 908 159±72 148±71** 182±88**
Normal daily activity
≤70 49 59±9 68±26* 60±13
71–180 504 127±30 122±33** 128±39
>180 261 238±47 223±51** 240±57
Total 814 158±67 151±64** 160±73
2 vs 1 and 3 vs 1.
*P<0.05; **P<0.001.
FSL, Free Style Libre; FSLCstrip, Free Style Libre Precision 
NeoPro strip.
Table 3 MAD and MARD of the (n=22) Eversense and FSL 
versus FSLCstrip measurements; glucose in mg/dL; results 

















Eversense 25±10 17±6** 17±6 13±6*
FSL 32±17 18±8* 20±7 12±5**
Exercise versus normal daily activity.
*P<0.01; **p<0.001.
FSL, Free Style Libre; FSLCstrip, Free Style Libre Precision 
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According to our findings, during periods of exer-
cise the FSL tends to show higher than actual glucose 
concentrations, while the Eversense does show an oppo-
site tendency. Whether these differences are caused by 
different algorithms translating the sensor signals into a 
glucose concentration value, or by another cause, is not 
known.
Taken together, this means that using interstitial 
glucose measurements during exercise is less accurate, 
which in its turn can have relevant consequences when 
inaccurate readings lead to wrong decisions. Users 
quickly learnt to handle the—sometimes—contradictory 
outcomes, often by assessing the trend information more 
than point measurements and controlling the readings 
through a capillary measurement when there was reason 
to doubt the result. Since we did not study these aspects, 
no formal conclusions can be drawn with regard to these 
aspects.
Figure 1 Comparison (Parkes error grids, ISO15197; 2013) between capillary measurements (Free Style Libre Precision 
NeoPro strip (FSLCstrip)) and Eversense readings during the exercise week (A) and normal daily activity week (B). Percentages 
of paired readings within error grid zones A, B, C, D and E are presented.
Table 4 Performance of the Eversense and FSL with FSLCstrip according to ICGMA guidelines, using FSLCstrip as reference
Exercise
(n=908)
Normal daily activity 
(n=814)
ICGMA: lower bound of one- sided
95% CI
Eversense   
Hypoglycemia (<70 mg/dL) 72% (44/61) 76% (37/49) >85% within ±15 mg/dL
  97% (59/61) 90% (44/49) >98% within ±40 mg/dL
Euglycemia (70–180 mg/dL) 56% (307/544) 69% (345/504) >70% within ±15%
  92% (498/544) 96% (486/504) >99% within ±40%
Hyperglycemia (>180 mg/dL) 68% (205/303) 75% (195/261) >80% within ±15%







FSL   
Hypoglycemia (<70 mg/dL) 61% (37/61) 78% (38/49) >85% within ±15 mg/dL
92% (56/61) 100% (49/49) >98% within ±40 mg/dL
Euglycemia (70–180 mg/dL) 47% (255/544) 67% (337/504) >70% within ±15%
90% (490/544) 96% (483/504) >99% within ±40%
Hyperglycemia (>180 mg/dL) 47% (142/303) 81% (212/261) >80% within ±15%
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Providing a definitive explanation for the apparent 
different behavior of interstitial glucose sensors during 
NDA and during intensive exercise is complex. The more 
intensive the exercise, the more circulatory, tissue and 
interstitial changes will occur.7 Rate of glucose change and 
interstitial fluid flow will increase, possibly influencing the 
amount of glucose passing the FSL sensor per time unit. 
One possible explanation, at least partly, for the increased 
MARD during activity may be that the changes in inter-
stitial readings lag behind the changes in blood glucose 
during prolonged aerobic exercise, which will contribute 
to an increase in MARD during exercise, as shown by Zaha-
rieva et al.19
Others possible causes include outside and skin tempera-
ture, weather conditions, intensity of exercise and degree of 
insulation caused by clothing. Furthermore, since nobody 
will exercise 24 hours per day, periods of exercise will be 
alternated with periods of rest and less efforts during the 
exercise week. This also will have its influences.
Our study does have strengths and limitations. From a 
user’s point of view, testing in a real- life setting yields results, 
which often will be more applicable and recognizable than 
results obtained in a laboratory setting. Even if results 
during real life use are not as accurate as hoped for, studies 
like ours help to recognize the limitations and pitfalls of 
the use of rt- CGM and FGM under various circumstances.
One limitation of this study is our failure to ask the 
participants to exactly note down their actual time biking. 
Therefore, we could not perform a subanalysis of data 
acquired during the 24 hours of the exercise days during 
the exercise itself, and during the period(s)) outside the 
exercise hours. Speculating on whether that would have 
influenced the results, one should keep in mind that 
when discontinuing exercise, the interstitial situation will 
not immediately return to normal, nor will other possible 
influencing factors, such as insulin sensitivity. Furthermore, 
the influence of altitude is also unknown since we did not 
register altitude time over. As oxygen availability is 80% 
at 2000 m altitude and 75% at 2500 m altitude, this could 
have influenced the results.20 Theoretically, this difference 
in oxygen availability might influence interstitial oxygen 
availability, which in turn might affect glucose oxidation 
rate. During our study, time at altitude was limited; further-
more, one has to keep in mind that by mountain biking 
at altitude the primary demand will be to adjust breathing 
frequency and intensity according to the skeletal and 
cardiac muscle oxygen needs. Since this will be different 
for each individual, we felt it impossible to introduce a reli-
able correction for that factor. In addition, the influence 
of, among others, differences in environmental tempera-
ture, effects of altitude and concomitant decrease in partial 
oxygen pressure and humidity and participants’ hydration 
were not systematically assessed. Therefore, we could not 
correct for the possible influence of these factors. In a next 
study, we will need to combine FGM and rt- CGM registra-
tions with additional devices to measure these factors. That 
would also allow a more detailed analysis of the influence 
of exercise proper, the resting periods during the exercise 
week (including sleeping) and a separate period of NDA.
Of notice, during the present study the first version of 
the FSL was used, thus missing the hypoglycemia alarm 
incorporated in the more recent FSL version.
Another major limitation is of course the use of a capil-
lary glucose measurement using a glucose strip as the 
comparative method instead of, for example, a Yellow 
Springs Analyzer or glucose hexokinase measurement. In 
our opinion, the use of a Precision Neo Pro as ‘gold stan-
dard’ is justifiable, since this strip is aligned with NIST stan-
dards to the gold reference method.16 A further limitation 
is that the majority of the persons included in this study 
were male, possibly limiting the generalizability of our 
results.
CONCLUSIONS
During exercise compared with daily life activities, inter-
stitial glucose readings with both the Eversense (fluores-
cence based) and the FSL (glucose oxidase based) were 
less accurate, often with clinically relevant differences, 
Figure 2 Comparison (Parkes error grids, ISO15197; 2013) between capillary measurements (Free Style Libre Precision 
NeoPro strip (FSLCstrip)) and Free Style Libre (FSL) readings during the exercise week (A) and normal daily activity week (B). 
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compared with capillary measurements. This phenom-
enon was present throughout the whole range of glucose 
concentrations.
Even when acknowledging the limitations of a study in a 
real- life setting, users and healthcare providers should be 
aware of this and be given proper education with regard to 
the described phenomenon.
Although we did not formally test the described short-
comings during exercise, the vast majority of users considers 
using any form of CGM as a valuable tool for glucose moni-
toring, and gladly accept a lesser performance in exchange 
for more detailed information on glucose levels and 
glucose trends.
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